. Author manuscript; available in PMC: 2011 Sep 1.

Published in final edited form as: Cytometry B Clin Cytom. 2010 Jun 11;78(5):329–337. doi: 10.1002/cyto.b.20528

TABLE 3.

Cell and Cell Derived Biomarkers

Marker Type	H	ES	LT	P
CD133⁺ PC	954 (712–157)	1052 (538–1277)	639 (448–1243)	0.08
CD34⁺ PC	2676 (1763–4644)	3432 (2153–4125)	1818 (1341–3268)	0.06
CD133⁺ CD34⁺ PC	778 (618–1251)	868 (407–1228)	605 (356–1208)	0.15
CD133⁺ VEGF-R2⁺ PAC	8.6 (0–20)	18.3 (0–21)	0 (0–9)^#	0.04^*
CD34⁺ VEGF-R2⁺ PAC	15.3 (9–26)	7.9 (6–40)	8.0 (0–18) ^#	0.03^*
CD133⁺ CD34⁺ VEGF-R2⁺ PAC	6.9 (0–12)	0 (0–20)	0 (0–7)^‖	0.04^*
CD144⁺ MPs	204 (93–411)	453 (187–616)	571 (207–892)^‖	0.03^*
CD41⁺ MPs	300 (155–583)	693 (239–894)	367 (258–939)^‖	0.03^*
CD14⁺ MPs	120 (68–347)	340 (178–469)	230 (77–488)	0.15
AnnV⁺ MPs	355 (240–760)	761 (449–996)^¶	682 (330–1044)^‖	0.02^*
nM of PS⁺ MPs	0.31 (0.21–0.36)	0.27 (0.16–0.40)	0.45 (0.28–0.56)^‖^#	0.02^*

Data are medians (25%–75% Interquartile Range). P(A)C values correspond to Cells/mL, MP values correspond to MPs/µL except PS⁺ MPs which corresponds to nM of PS equivalent by plate based assay. H indicates healthy; ES, early stage diabetes; LT, long term diabetes.

P<0.05

Post-hoc comparison significance levels (not adjusted for multiple comparisons)

^†

P < 0.01 LT vs. H,

^‡

P <0.01 ES vs. H,

^§

P < 0.01 LT vs. ES

^‖

P< 0.05 LT vs. H,

^¶

P < 0.05 ES vs. H,

P < 0.05 LT vs. ES

P calculated by JT test to test for differences between the three groups. Post-hoc analyses between patient groups used the two sample Wilcoxon test.